Maria Duca

List of Publications by Year
in descending order

40 papers	1,099 citations	471509 17 h-index	414414 32 g-index
43 all docs	43 docs citations	43 times ranked	1143 citing authors

#	Article	IF	Citations
1	The triple helix: 50 years later, the outcome. Nucleic Acids Research, 2008, 36, 5123-5138.	14.5	302
2	Targeting the Production of Oncogenic MicroRNAs with Multimodal Synthetic Small Molecules. ACS Chemical Biology, 2014, 9, 711-721.	3.4	99
3	Targeting DNA base pair mismatch with artificial nucleobases. Advances and perspectives in triple helix strategy. Organic and Biomolecular Chemistry, 2011, 9, 326-336.	2.8	60
4	Synthetic small-molecule RNA ligands: future prospects as therapeutic agents. MedChemComm, 2019, 10, 1242-1255.	3.4	53
5	Synthesis and Biological Activity of Sulfonamide Derivatives of Epipodophyllotoxin. Journal of Medicinal Chemistry, 2004, 47, 2365-2374.	6.4	42
6	Synthesis and Biological Study of a New Series of 4â€˜-Demethylepipodophyllotoxin Derivatives. Journal of Medicinal Chemistry, 2005, 48, 593-603.	6.4	42
7	Oncogenic MicroRNAs Biogenesis as a Drug Target: Structureâ€“Activity Relationship Studies on New Aminoglycoside Conjugates. Chemistry - A European Journal, 2016, 22, 5350-5362.	3.3	41
8	Modulation of oncogenic miRNA biogenesis using functionalized polyamines. Scientific Reports, 2018, 8, 1667.	3.3	39
9	Design of novel RNA ligands that bind stemâ€“bulge HIV-1 TAR RNA. Chemical Communications, 2010, 46, 6162.	4.1	33
10	Artificial Nucleobaseâ€“Amino Acid Conjugates: A New Class of TAR RNA Binding Agents. Chemistry - A European Journal, 2014, 20, 2071-2079.	3.3	33
11	Small-molecule approaches toward the targeting of oncogenic miRNAs: roadmap for the discovery of RNA modulators. Future Medicinal Chemistry, 2016, 8, 803-816.	2.3	31
12	Selective Generation and Reactivity of 5â€²-Adenosinyl and 2â€²-Adenosinyl Radicals. Chemistry - A European Journal, 2004, 10, 1249-1255.	3.3	28
13	Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides. Nucleic Acids Research, 2006, 34, 1900-1911.	14.5	27
14	Building of neomycinâ€“nucleobaseâ€“amino acid conjugates for the inhibition of oncogenic miRNAs biogenesis. Organic and Biomolecular Chemistry, 2018, 16, 6262-6274.	2.8	27
15	Fluorescent labeling of human mesenchymal stem cells by thiophene fluorophores conjugated to a lipophilic carrier. Chemical Communications, 2010, 46, 7948.	4.1	23
16	Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting. Bioorganic and Medicinal Chemistry, 2015, 23, 5334-5344.	3.0	18
17	Tandem Azide-Alkyne 1,3-Dipolar Cycloaddition/Electrophilic Addition: A Concise Three-Component Route to 4,5-Disubstituted Triazolyl-Nucleosides. Synlett, 2009, 2009, 2123-2126.	1.8	17
18	Design and Implementation of Synthetic RNA Binders for the Inhibition of miR-21 Biogenesis. ACS Medicinal Chemistry Letters, 2021, 12, 899-906.	2.8	17

#	Article	IF	Citations
19	Contributions of the D-Ring to the Activity of Etoposide against Human Topoisomerase IIÎ±: Potential Interactions with DNA in the Ternary Enzymeâ€“Drugâ€“DNA Complex. Biochemistry, 2011, 50, 5058-5066.	2.5	16
20	Aminoglycoside Conjugation for RNA Targeting: Antimicrobials and Beyond. Chemistry - A European Journal, 2020, 26, 12273-12309.	3.3	14
21	Design of Multimodal Small Molecules Targeting miRNAs Biogenesis: Synthesis and In Vitro Evaluation. Methods in Molecular Biology, 2017, 1517, 137-154.	0.9	13
22	Exploring Heterocycle-Spermine Conjugates as Modulators of Oncogenic microRNAs Biogenesis. ACS Omega, 2018, 3, 16500-16508.	3.5	13
23	TargetingMDR1Gene: Synthesis and Cellular Study of Modified Daunomycin-Triplex-Forming Oligonucleotide Conjugates Able to Inhibit Gene Expression in Resistant Cell Lines. Molecular Pharmacology, 2008, 73, 1568-1577.	2.3	12
24	Novel carbamate derivatives of 4-Î²-amino-4â€²-O-demethyl-4-desoxypodophyllotoxin as inhibitors of topoisomerase II: synthesis and biological evaluation. Organic and Biomolecular Chemistry, 2005, 3, 1074-1080.	2.8	11
25	Aminoacylation of transfer RNAs with one and two amino acids. Methods, 2008, 44, 87-99.	3.8	9
26	Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BrafV600E Melanoma. Cancers, 2020, 12, 1500.	3.7	9
27	Modeling the reactive properties of tandemly activated tRNAs. Organic and Biomolecular Chemistry, 2008, 6, 3292.	2.8	8
28	Potent Tyrosinase Inhibitory Activity of Curcuminoid Analogues and Inhibition Kinetics Studies. Cosmetics, 2021, 8, 35.	3.3	8
29	Triple Helix-Forming Oligonucleotides Conjugated to New Inhibitors of Topoisomerase II:â€‰ Synthesis and Binding Properties. Bioconjugate Chemistry, 2005, 16, 873-884.	3.6	7
30	Synthesis of bisaminoacylated pdCpAs and tandemly activated transfer RNAs. Bioorganic and Medicinal Chemistry, 2007, 15, 4629-4642.	3.0	7
31	Unveiling RNAâ€Binding Properties of Verapamil and Preparation of New Derivatives as Inhibitors of HIVâ€1 Tatâ€TAR Interaction. ChemPlusChem, 2020, 85, 207-216.	2.8	7
32	The Chemical Biologyâ€Medicinal Chemistry Continuum: EFMCâ€²s Vision. ChemBioChem, 2021, 22, 2823-2825.	2.6	7
33	New Chemical Modalities Enabling Specific RNA Targeting and Degradation: Application to SARS-CoV-2 RNA. ACS Central Science, 2020, 6, 1647-1650.	11.3	6
34	Structural Basis for the Exceptional Stability of Bisaminoacylated Nucleotides and Transfer RNAs. Journal of the American Chemical Society, 2011, 133, 11368-11377.	13.7	5
35	Functionalized C-nucleosides as remarkable RNA binders: targeting of prokaryotic ribosomal A-site RNA. Chemical Communications, 2019, 55, 10432-10435.	4.1	5
36	Development of 2-deoxystreptamineâ€“nucleobase conjugates for the inhibition of oncogenic miRNA production. RSC Medicinal Chemistry, 2022, 13, 311-319.	3.9	4

#	Article	IF	Citations
37	Sequence-Specific Base Pair Mimics Are Efficient Topoisomerase IB Inhibitors. Biochemistry, 2012, 51, 43-51.	2.5	3
38	Differentiation of Cancer Stem Cells by Using Synthetic Small Molecules: Toward New Therapeutic Strategies against Therapy Resistance. ChemMedChem, 2021, 16, 14-29.	3.2	2
39	New Chemical Modalities Enabling Specific RNA Targeting and Degradation: Application to SARS-CoV-2 RNA. ACS Central Science, 2020, 6, 1647-1650.	11.3	1
40	Frontispiece: Aminoglycoside Conjugation for RNA Targeting: Antimicrobials and Beyond. Chemistry - A European Journal, 2020, 26, .	3.3	0